HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wisconsin Doctor’s CBD Nasal Sprays, Topical Offered OTC Diagnosed As Unapproved Drugs

Executive Summary

Nasadol CBD Nasal Sprays not only are violative for claims unallowed for CBD, but for containing CBD. FDA also warns online pharmacy about fraudulent OTC COVID-19 cure kit.

You may also be interested in...



Still No Appetite At US FDA For CBD In Food

Three years after similar warnings to make same impression, FDA warns five firms about using in food or beverage products CBD, the cannabinoid most commonly found in US, and delta-8 THC, a subject of ongoing discussion over whether it qualifies as hemp. One firm also warned about CBD in sunscreen.

To Reach Sweet Spot In CBD Topical Permeation, Sweet Earth Relies On Nanotechnology

Sweet Earth conducts research with NAVCO Pharmaceuticals to confirm previous finding that beneficial effect of CBD is significantly impacted by skin permeation facilitated by nanotechnology. Canadian firm's CBD topicals are formulated with 70 nanometer particles.

Herbal Sprays, Nasal Swabs Latest Additions On List Of Fraudulent COVID Cures Offered In US

“Germaphobe’s Delight Spray” was “re-vamped … to better meet the challenges of COVID-19,” Fopo Jordan’s Crossing Herbal claimed. Halodine LLC claimed its nasal sanitizer “kills SARS-CoV-2 (the virus that causes COVID-19) in less than 15 seconds.”

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS151617

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel